GlassScriptPhysician profile
Eduardo G Calderon
NPI 1952379109
$18,525.51
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $6,618 · 2021: $3,651 · 2022: $5,593 · 2023: $1,261 · 2024: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.90 |
| Education | $116.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $14,908.94 | 2019-2024 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $1,131.25 | 2019-2024 | Epclusa |
| Merck Sharp & Dohme LLC | $707.04 | 2019-2024 | Delstrigo, Pifeltro, Recarbrio |
| Janssen Biotech, INC. | $587.84 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $292.09 | 2021-2024 | Kimyrsa, Rezzayo, Vabomere |
| Janssen Products, LP | $243.99 | 2019-2022 | |
| Astellas Pharma US INC | $132.52 | 2019-2024 | |
| Theratechnologies INC. | $132.01 | 2019-2022 | |
| Abbvie INC. | $75.19 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $65.94 | 2021-2023 | |
| Vyera Pharmaceuticals, LLC | $50.13 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $34.15 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $28.72 | 2019-2020 | |
| Napo Pharmaceuticals INC | $23.36 | 2022 | |
| United Therapeutics Corporation | $21.35 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.69 | 2023 | Ofev |
| Corcept Therapeutics | $18.20 | 2020 | |
| Sanofi Pasteur INC. | $16.84 | 2019 | |
| Shionogi INC | $16.52 | 2023 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.